Evidence map›Paper›PMID 33441691›Full record

ArticleScientific reports2021

Lipid droplet biogenesis and COX-2 pathway activation are triggered by Barrett's esophagus and adenocarcinoma, but not esophageal squamous cell carcinoma risk factors.

N Carrossini, N Meireles Da Costa, E Andrade-Barreto, V P L Sousa, P Nicolau-Neto, P T Souza-Santos, G R Mansur, L Wernersbach, P T Bozza, J P B Viola and 1 more

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

N CarrossiniMolecular Carcinogenesis Program (PCM), Research Coordination (CPQ), Brazilian National Cancer Institute (INCA), Rua André Cavalcanti, 37-Centro, 6º andar, Rio de Janeiro, RJ, CEP 20231-050, Brazil.
N Meireles Da CostaMolecular Carcinogenesis Program (PCM), Research Coordination (CPQ), Brazilian National Cancer Institute (INCA), Rua André Cavalcanti, 37-Centro, 6º andar, Rio de Janeiro, RJ, CEP 20231-050, Brazil.
E Andrade-BarretoLaboratory of Immunopharmacology, Oswaldo Cruz Institute-FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro, RJ, CEP 21040-360, Brazil.
V P L SousaMolecular Carcinogenesis Program (PCM), Research Coordination (CPQ), Brazilian National Cancer Institute (INCA), Rua André Cavalcanti, 37-Centro, 6º andar, Rio de Janeiro, RJ, CEP 20231-050, Brazil.
P Nicolau-NetoMolecular Carcinogenesis Program (PCM), Research Coordination (CPQ), Brazilian National Cancer Institute (INCA), Rua André Cavalcanti, 37-Centro, 6º andar, Rio de Janeiro, RJ, CEP 20231-050, Brazil.
P T Souza-SantosMolecular Carcinogenesis Program (PCM), Research Coordination (CPQ), Brazilian National Cancer Institute (INCA), Rua André Cavalcanti, 37-Centro, 6º andar, Rio de Janeiro, RJ, CEP 20231-050, Brazil.
G R MansurEndoscopy Section, Brazilian National Cancer Institute-INCA, Praça Cruz Vermelha, 23, 8º andar, Centro, Rio de Janeiro, RJ, CEP 20230-130, Brazil.
L WernersbachPathology Division, Brazilian National Cancer Institute-INCA, Rua Cordeiro da Graça, 156, Santo Cristo, Rio de Janeiro, RJ, CEP 20220-400, Brazil.
P T BozzaLaboratory of Immunopharmacology, Oswaldo Cruz Institute-FIOCRUZ, Av. Brasil 4365, Manguinhos, Rio de Janeiro, RJ, CEP 21040-360, Brazil.
J P B ViolaProgram of Immunology and Tumor Biology, Brazilian National Cancer Institute-INCA, Rua André Cavalcanti, 37, 5º andar, Centro, Rio de Janeiro, RJ, CEP 20231-050, Brazil.
Luis Felipe Ribeiro PintoMolecular Carcinogenesis Program (PCM), Research Coordination (CPQ), Brazilian National Cancer Institute (INCA), Rua André Cavalcanti, 37-Centro, 6º andar, Rio de Janeiro, RJ, CEP 20231-050, Brazil. lfrpinto@inca.gov.br.
Instituto Nacional do Câncer · BRFundação Oswaldo Cruz · BRUniversidade do Estado do Rio de Janeiro · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Esophageal cancer (EC) is an aggressive disease, presenting two main histological subtypes: adenocarcinoma (EAC) and squamous cell carcinoma (ESCC). The two EC subtypes widely differ concerning virtually all factors. ESCC development is mainly associated with tobacco and alcohol abuse, whereas obesity and chronic gastroesophageal reflux disease (GERD) are important risk factors not only for EAC, but also for for Barrett's esophagus (BE), an intestinal metaplasia that precedes EAC. Obesity triggers ectopic lipid droplets (LD) accumulation in non-adipose tissues. LD are organelles involved in cell metabolism, signaling, proliferation and production of inflammatory mediators. Therefore, the aim of this work was to investigate LD occurrence and role in EC. This study shows progressive LD levels increase along EAC development, in esophageal samples from non-obese through obese individuals, as well as BE, and EAC patients, whereas no significant changes were observed in ESCC samples, when compared to non-tumor samples. Additionally, in order to mimic BE and EAC risk factors exposure, a non-tumor esophageal cell line was incubated with oleic acid (OA) and acidified medium and/or deoxycholic acid (DCA), revealing a significant increment in LD amount as well as in COX-2 and CXCL-8 expression, and in IL-8 secretion. Further, COX-2 expression and LD amount presented a significant positive correlation and were detected co-localized in EAC, but not in ESCC, suggesting that LD may be the site for eicosanoid production in EAC. In conclusion, this study shows that obesity, and BE- and EAC-associated inflammatory stimuli result in a gradual increase of LD, that may be responsible for orchestrating inflammatory mediators' production and/or action, thus contributing to BE and EAC genesis and progression.

Indexed as

AdenocarcinomaBarrett EsophagusCell LineCyclooxygenase 2Esophageal NeoplasmsEsophageal Squamous Cell CarcinomaEsophagusGastroesophageal RefluxHumansInflammationLipid DropletsRisk FactorsSignal TransductionCyclooxygenase 2

Identifiers

PMID33441691
PMCPMC7807011
OpenAlexW3120109335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.